Linaxa D 5/10 Tablet is a combination oral antidiabetic medication containing Dapagliflozin 10 mg and Linagliptin 5 mg, indicated for the management of type 2 diabetes mellitus. Dapagliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor, reduces renal glucose reabsorption, promoting glycosuria and thereby lowering plasma glucose levels. Linagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, enhances incretin hormone activity, increasing insulin secretion and decreasing glucagon release in a glucose-dependent manner. This dual mechanism provides complementary glycemic control by targeting both renal glucose excretion and pancreatic hormone regulation. Linaxa D 5/10 is typically prescribed as an adjunct to diet and exercise to improve glycemic control in adults inadequately controlled on monotherapy or other antidiabetic agents. It may also be used in combination with insulin. The fixed-dose combination offers convenience and may improve patient adherence. Common adverse effects include urinary tract infections, genital mycotic infections, nasopharyngitis, and hypoglycemia, especially when used with insulin or sulfonylureas. Caution is advised in patients with renal impairment, hepatic dysfunction, or risk factors for ketoacidosis. Regular monitoring of renal function, blood glucose, and potential side effects is recommended during therapy with Linaxa D 5/10 Tablet.